Skip to main content

Table 2 Risk factors for overall survival, time to progress, and hepatic metastasis-free survival in the CRC patients undergoing curative surgical resection

From: Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

Variable Overall survival Time to progress Hepatic metastasis-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Anti-HBc                   
 Positive 1.219 0.771–1.926 0.397     1.175 0.757–1.823 0.473     0.879 0.412–1.878 0.74    
 Negative Reference       Reference       Reference      
FIB-4                   
  ≥ 1.45 1.523 0.944–2.459 0.085     1.032 0.629–1.693 0.9     1.108 0.493–2.489 0.804    
 < 1.45 Reference       Reference       Reference      
NLR                   
  ≥ 3.4 1.982 1.207–3.254 0.007* 1.838 1.119–3.02 0.016* 1.866 1.146–3.04 0.012* 1.783 1.094–2.906 0.02* 2.367 1.108–5.059 0.026* 2.231 1.043–4.773 0.039*
 < 3.4 Reference       Reference       Reference      
Anti-HBs                   
 Positive 1.122 0.695–1.81 0.638     1.037 0.652–1.648 0.879     0.965 0.442–2.107 0.929    
 Negative Reference       Reference       Reference      
HBsAg                   
 Positive 2.48 0.905–6.793 0.077     2.195 0.803–5.999 0.125     2.927 0.697–12.295 0.143    
 Negative Reference       Reference       Reference      
Retrieved LN                  
  ≥ 12 0.715 0.451–1.132 0.153     0.789 0.506–1.232 0.297     1.565 0.671–3.647 0.3    
 < 12 Reference       Reference       Reference      
Neoadjuvant therapy                 
 Yes 0.808 0.326–2 0.644     1.213 0.585–2.514 0.604     1.285 0.39–4.236 0.681    
 No Reference       Reference       Reference      
CEA (ng/ml)                  
 > 5 1.272 0.811–1.995 0.294     1.151 0.748–1.773 0.523     1.769 0.859–3.642 0.122    
  ≤ 5 Reference       Reference       Reference      
CA19-9(U/ml)                  
 > 37 2.352 1.371–4.035 0.002* 2.111 1.229–3.624 0.007* 1.548 0.871–2.751 0.136     1.157 0.404–3.315 0.787    
  ≤ 37 Reference       Reference       Reference      
TNM stage                  
 III 3.609 2.223–5.859 < 0.001* 3.511 2.162–5.702 < 0.001* 3.628 2.279–5.775 < 0.001* 3.579 2.247–5.699 < 0.001* 3.084 1.442–6.597 0.004* 2.985 1.394–6.391 0.005*
 II Reference       Reference       Reference      
Gender                   
 Male 1.035 0.651–1.644 0.885     1.16 0.741–1.815 0.517     1.771 0.789–3.979 0.166    
 Female Reference       Reference       Reference      
Age (years)                  
  ≥ 61 0.996 0.635–1.561 0.985     0.899 0.584–1.383 0.628     0.652 0.314–1.354 0.252    
 < 61 Reference       Reference      Reference      
  1. Abbreviations: anti-HBc antibodies to hepatitis B core antigen, anti-HBs antibodies to hepatitis B surface antigen, HBsAg hepatitis B surface antigen, NLR neutrophil to lymphocyte ratio; CA19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; PLT, platelets
  2. *Significant at P < 0.05